focus -WSS

focus

author：entertainment 2025-09-29 21:14:57 - browse：52739

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： As demand for Covid shots wanes, Moderna seeks its next success

focus

hotspot

WSS

Wildfire smoke exposes gaps in outdoor worker protections

State Dept. review finds Biden bears some blame for Afghanistan failures

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Virginia high school admissions case could be legal follow

In Memoriam: Notable people who died in 2023

George Santos makes 1st court appearance after pleading not guilty to 13 counts

leisure time

focus

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Scientists successfully use ultrasound imaging to map brain activity

Medical leaders decry Supreme Court decision on affirmative action

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Apple is now the first public company to be valued at $3 trillion

Lab trade group sues FDA to halt regulation of lab

Malaria cases in Florida and Texas: Here’s what you need to know

Akili, maker of video game for ADHD, to be acquired for 34 million

Virginia high school admissions case could be legal follow

George Santos makes 1st court appearance after pleading not guilty to 13 counts

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Heat waves linked to early deliveries, preterm births in new study

Bright Health sells Medicare Advantage business to Molina

Heat waves linked to early deliveries, preterm births in new study

Wildfire smoke exposes gaps in outdoor worker protections

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

focus

hotspot

Wikipedia

entertainment